A randomized, double-blind, placebo-controlled Phase 2 study using the rhinovirus challenge model to investigate the efficacy and safety of 2-Deoxy-D-glucose as pre-exposure prophylaxis.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509311-91-01

Acronym

2-DG-02

Enrollment

128

Registered

2024-02-14

Start date

2024-02-15

Completion date

2024-08-13

Last updated

2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinovirus-associated illness

Brief summary

The difference in the rate of rhinovirus-associated illness between 2-DG and placebo

Detailed description

Difference in number of infected subjects (defined by laboratory-confirmed infection), Difference in % of infected subjects (defined by laboratory-confirmed infection), Difference in Total Jackson Symptom Score, Difference in Duration of Illness between the groups, days 2-15, Occurrence of adverse events (AEs) and adverse drug reactions (ADRs)

Interventions

DRUGPlacebo for 2-deoxy-D-glucose

DRUG2-deoxy-D-glucose

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The difference in the rate of rhinovirus-associated illness between 2-DG and placebo	—

Secondary

Measure	Time frame
Difference in number of infected subjects (defined by laboratory-confirmed infection), Difference in % of infected subjects (defined by laboratory-confirmed infection), Difference in Total Jackson Symptom Score, Difference in Duration of Illness between the groups, days 2-15, Occurrence of adverse events (AEs) and adverse drug reactions (ADRs)	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026